H shares

Ping An Ranks 7th and Lufax 19th in 2020 BrandZ™ Top 100 Most Valuable Chinese Brands

Retrieved on: 
Thursday, October 15, 2020

HONG KONG, SHANGHAI, Oct.15, 2020 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or "The Group", HKEx: 2318; SSE: 601318) has maintained its top position among Chinese insurers and ranked second among financial brands the 2020 BrandZTop 100 Most Valuable Chinese Brands.

Key Points: 
  • HONG KONG, SHANGHAI, Oct.15, 2020 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or "The Group", HKEx: 2318; SSE: 601318) has maintained its top position among Chinese insurers and ranked second among financial brands the 2020 BrandZTop 100 Most Valuable Chinese Brands.
  • To some extent, Chinese brands have become world brand leaders by virtue of their high-quality products and world-class convenience.
  • In 2020, Ping An ranked 7th in the Forbes Global 2000 list and ranked 21st in the Fortune Global 500 list.
  • Ping An also ranked 38th in the 2020 WPP Kantar Millward Brown BrandZTM Top 100 Most Valuable Global Brands list.

Ping An Ranks 7th and Lufax 19th in 2020 BrandZ™ Top 100 Most Valuable Chinese Brands

Retrieved on: 
Thursday, October 15, 2020

HONG KONG, SHANGHAI, Oct.15, 2020 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or "The Group", HKEx: 2318; SSE: 601318) has maintained its top position among Chinese insurers and ranked second among financial brands the 2020 BrandZTop 100 Most Valuable Chinese Brands.

Key Points: 
  • HONG KONG, SHANGHAI, Oct.15, 2020 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or "The Group", HKEx: 2318; SSE: 601318) has maintained its top position among Chinese insurers and ranked second among financial brands the 2020 BrandZTop 100 Most Valuable Chinese Brands.
  • To some extent, Chinese brands have become world brand leaders by virtue of their high-quality products and world-class convenience.
  • In 2020, Ping An ranked 7th in the Forbes Global 2000 list and ranked 21st in the Fortune Global 500 list.
  • Ping An also ranked 38th in the 2020 WPP Kantar Millward Brown BrandZTM Top 100 Most Valuable Global Brands list.

Hovde Group Launches Asset Management Advisory Effort With Addition of Mark Timperman

Retrieved on: 
Tuesday, October 13, 2020

Hovde Group (Hovde), a leading full service investment bank and broker dealer that provides investment banking, capital markets, equity research, and sales and trading services focused on the financial services sector, today announced thatit has formed a new practice to advise asset management and wealth management companies, led by Mark Timperman as Managing Director and Head of Asset Management Investment Banking.

Key Points: 
  • Hovde Group (Hovde), a leading full service investment bank and broker dealer that provides investment banking, capital markets, equity research, and sales and trading services focused on the financial services sector, today announced thatit has formed a new practice to advise asset management and wealth management companies, led by Mark Timperman as Managing Director and Head of Asset Management Investment Banking.
  • Mark joins Hovde with over twenty years of financial institutions investment banking experience primarily serving the asset management industry.
  • Most recently he served as Head of Asset Management Investment Banking at Wells Fargo Securities, LLC where he focused on strategic advisory and capital raising for traditional and alternative asset managers, wealth management and retirement services firms and broker-dealers.
  • As Hovde Group continues to look to expand our services we are excited to bring Mark on as our Head of Asset Management Investment Banking, commented Kirk Hovde, Managing Principal & Head of Investment Banking.

Zai Lab Announces Closing of Hong Kong Secondary Listing

Retrieved on: 
Monday, September 28, 2020

SHANGHAI and SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab or the Company) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the Hong Kong Stock Exchange) under the stock code 9688 and the closing of its previously-announced Hong Kong secondary listing (the Hong Kong Secondary Listing) of 10,564,050 new ordinary shares (the Offer Shares or Shares) which comprises an international offering (the International Offering) and a Hong Kong public offering (the Hong Kong Public Offering, and together with the International Offering, the Offering).

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab or the Company) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the Hong Kong Stock Exchange) under the stock code 9688 and the closing of its previously-announced Hong Kong secondary listing (the Hong Kong Secondary Listing) of 10,564,050 new ordinary shares (the Offer Shares or Shares) which comprises an international offering (the International Offering) and a Hong Kong public offering (the Hong Kong Public Offering, and together with the International Offering, the Offering).
  • The gross proceeds to Zai Lab from this Offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately HK$5.94 billion.
  • and Citigroup Global Markets Asia Limited (or its affiliate, as the case may be)are the joint sponsors, joint global coordinators, joint bookrunners and joint lead managers for the proposed Hong Kong Secondary Listing.
  • This press release has not been reviewed or approved by the Hong Kong Stock Exchange or the Securities and Futures Commission of Hong Kong.

Baozun Announces Pricing of Global Offering

Retrieved on: 
Wednesday, September 23, 2020

SHANGHAI, China, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Baozun Inc. (Nasdaq: BZUN) (Baozun or the Company), the leading brand e-commerce service partner that helps brands execute their e-commerce strategies in China, today announced the pricing of the global offering (the Global Offering) of 40,000,000 Class A ordinary shares (the Shares), which comprises an international offering and a Hong Kong public offering.

Key Points: 
  • SHANGHAI, China, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Baozun Inc. (Nasdaq: BZUN) (Baozun or the Company), the leading brand e-commerce service partner that helps brands execute their e-commerce strategies in China, today announced the pricing of the global offering (the Global Offering) of 40,000,000 Class A ordinary shares (the Shares), which comprises an international offering and a Hong Kong public offering.
  • The gross proceeds to the Company from the Global Offering, before deducting underwriting fees and the offering expenses, are expected to be approximately HK$3,316.0 million.
  • Citigroup Global Markets Asia Limited, CMB International Capital Limited and Credit Suisse (Hong Kong) Limited are the joint sponsors, joint global coordinators, joint bookrunners and joint lead managers for the Global Offering.
  • China International Capital Corporation Hong Kong Securities Limited is acting as a joint global coordinator, joint bookrunner and joint lead manager for the Global Offering.

Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012

Retrieved on: 
Thursday, September 17, 2020

Today Mr. Alon Bloomenfeld announced that Raziel Therapeutics has entered into a license agreement with Tianjin JuveStar Biotech Co., Ltd., (JuveStar), a company invested and incubated by the venture capital arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK).

Key Points: 
  • Today Mr. Alon Bloomenfeld announced that Raziel Therapeutics has entered into a license agreement with Tianjin JuveStar Biotech Co., Ltd., (JuveStar), a company invested and incubated by the venture capital arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK).
  • "Fosun Pharma is one of the leading healthcare companies in China, with expertise and access to both the aesthetic and therapeutic markets.
  • We see Fosun Pharma as an ideal partner to commercialize RZL-012 in the fast-growing aesthetic Chinese market, said Alon Bloomenfeld, president and chief executive officer at Raziel Therapeutics.
  • Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China.

Zai Lab Launches Hong Kong Secondary Listing

Retrieved on: 
Wednesday, September 16, 2020

SHANGHAI and SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab or the Company) (NASDAQ:ZLAB), an innovative commercial stage biopharmaceutical company, today announced the launch of its Hong Kong public offering (the Hong Kong Public Offering), which forms part of the global offering (the Offering) of 10,564,050 new ordinary shares (the Offer Shares or Shares) and listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the Hong Kong Stock Exchange) under the stock code 9688.

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab or the Company) (NASDAQ:ZLAB), an innovative commercial stage biopharmaceutical company, today announced the launch of its Hong Kong public offering (the Hong Kong Public Offering), which forms part of the global offering (the Offering) of 10,564,050 new ordinary shares (the Offer Shares or Shares) and listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the Hong Kong Stock Exchange) under the stock code 9688.
  • Upon listing in Hong Kong, the ordinary shares listed on the Hong Kong Stock Exchange will be fully fungible with the ordinary shares represented by the ADSs listed on Nasdaq.
  • Zai Lab has decided to adopt a fully electronic application process for the Hong Kong Public Offering, with no printed copies of prospectuses or application forms to the public in relation to the Hong Kong Public Offering.
  • The Hong Kong Public Offering will commence at 9:00 a.m. on Thursday, September 17, 2020 Hong Kong time and will close at 12:00 noon on Tuesday, September 22, 2020 Hong Kong time.

ZTO EXPRESS Launches Hong Kong Initial Public Offering

Retrieved on: 
Wednesday, September 16, 2020

SHANGHAI, Sept. 16, 2020 /PRNewswire/ -- ZTO Express (Cayman) Inc. (NYSE: ZTO) (the "Company" or "ZTO EXPRESS"; Stock code: 2057.HK), a leading express delivery company in China, today announced the launch of its Hong Kong public offering (the "Hong Kong Public Offering"), whichforms part of the global offering (the "Offering") of 45,000,000 new Class A ordinary shares (the "Offer Shares") and listing of its Class A ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") under the stock code "2057".

Key Points: 
  • SHANGHAI, Sept. 16, 2020 /PRNewswire/ -- ZTO Express (Cayman) Inc. (NYSE: ZTO) (the "Company" or "ZTO EXPRESS"; Stock code: 2057.HK), a leading express delivery company in China, today announced the launch of its Hong Kong public offering (the "Hong Kong Public Offering"), whichforms part of the global offering (the "Offering") of 45,000,000 new Class A ordinary shares (the "Offer Shares") and listing of its Class A ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") under the stock code "2057".
  • The Offering initially comprises 2,250,000new Offer Shares under the Hong Kong Public Offering and42,750,000 new Offer Shares for the international offering (the "International Offering"), representing approximately 5% and 95% of the total number of Offer Shares in the Offering, respectively, subject to re-allocation and over-allotment.
  • The offer price for the Hong Kong Public Offering (the "Hong Kong Offer Price") will be no more than HK$268 per Class A ordinary share (the "Maximum Offer Price").
  • The Hong Kong Public Offering will commence at 9:00 a.m. on Thursday,17 September2020 Hong Kong time and will close at 12:00 noon on Tuesday,22 September2020 Hong Kong time.

RMB Capital Ranked Among Barron’s Top 100 RIA Firms

Retrieved on: 
Monday, September 14, 2020

RMB Capital (RMB), an independent investment advisory firm with approximately $8.7 billion in assets under management1 (estimated as of June 30, 2020), announced that it was once again named by Barrons magazine as one of the Top 100 RIA Firms in the nation.

Key Points: 
  • RMB Capital (RMB), an independent investment advisory firm with approximately $8.7 billion in assets under management1 (estimated as of June 30, 2020), announced that it was once again named by Barrons magazine as one of the Top 100 RIA Firms in the nation.
  • The Barrons annual ranking is responsive to trends and important issues in the industry, and it focuses on the criteria that should matter most to investors.
  • AUM reflects net assets under management for private funds and mutual funds managed by RMB Capital, while RAUM reflects gross assets under management.
  • AUM also includes RMB Wests assets under advisement, which are not included in RMB Capitals RAUM.

China Aircraft Imports Report 2020: Impact of the Pandemic and Forecasts to 2024

Retrieved on: 
Friday, September 11, 2020

DUBLIN, Sept. 11, 2020 /PRNewswire/ -- The "Research Report on Aircraft Imports in China 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 11, 2020 /PRNewswire/ -- The "Research Report on Aircraft Imports in China 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • With the development of China's general aviation market, the number of small aircraft imported into the Chinese market would continue to rise.
  • The top three airlines in China are Air China, China Eastern Airlines, and China Southern Airlines.
  • Due to the lack of aircraft manufacturing capacity of Chinese local enterprises, it is estimated that China's civil aviation aircraft will mainly rely on imports from 2020 to 2024.